```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6807 Introduced in House (IH)]

<DOC>

118th CONGRESS
  1st Session
                                H. R. 6807

    To increase funding for cancer research by the National Cancer 
  Institute to be more in proportion to the mortality rates of cancer.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           December 14, 2023

Mr. Fitzpatrick (for himself and Mrs. Dingell) introduced the following 
  bill; which was referred to the Committee on Appropriations, and in 
 addition to the Committee on Energy and Commerce, for a period to be 
subsequently determined by the Speaker, in each case for consideration 
  of such provisions as fall within the jurisdiction of the committee 
                               concerned

_______________________________________________________________________

                                 A BILL

 
    To increase funding for cancer research by the National Cancer 
  Institute to be more in proportion to the mortality rates of cancer.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Knock Out Cancer Act'' or the ``KO 
Cancer Act''.

SEC. 2. INCREASING NCI BUDGET FOR CANCER RESEARCH.

    To conduct or support cancer research, there is hereby 
appropriated, for each of fiscal years 2024 through 2028, to the 
National Cancer Institute, out of amounts in the Treasury not otherwise 
appropriated, an amount that is equal to 25 percent of the total amount 
appropriated to the National Cancer Institute for fiscal year 2022, to 
remain available until expended. Amounts appropriated pursuant to the 
preceding sentence shall be in addition to amounts otherwise made 
available to the National Cancer Institute.

SEC. 3. REPORT TO CONGRESS ON CANCER DRUG SHORTAGES.

    (a) Study.--The Secretary of Health and Human Services, acting 
through the Commissioner of Food and Drugs, in collaboration with such 
other agencies as the Secretary deems necessary, shall study the 
reasons for cancer drug shortages, including--
            (1) economic reasons;
            (2) supply chain failures;
            (3) delays and other complications relating to--
                    (A) the development of cancer drugs; and
                    (B) the approval of such drugs by the Food and Drug 
                Administration; and
            (4) insufficient generic drugs and biosimilar biological 
        products.
    (b) Report.--
            (1) In general.--Not later than 1 year after the date of 
        enactment of this Act, the Secretary of Health and Human 
        Services, acting through the Commissioner of Food and Drugs, 
        shall complete the study under subsection (a) and submit a 
        report to the appropriate committees of the Congress on the 
        results of such study.
            (2) Recommendations.--The report under paragraph (1) shall 
        include recommendations for addressing the reasons for cancer 
        drug shortages.
                                 <all>
```